A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.12503
Abstract: Enzalutamide is an androgen receptor inhibitor approved for treatment of metastatic castration‐resistant prostate cancer. Enzalutamide is highly protein bound and eliminated primarily by hepatic metabolism; therefore, it is important to understand whether enzalutamide pharmacokinetics is… read more here.
Keywords: comparison pharmacokinetics; subjects hepatic; safety enzalutamide; hepatic impairment ... See more keywords